ClinicalTrials.gg
CompletedNCT00391898Updated Mar 15, 2011Results posted

Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off

A Phase 4 interventional study of Levodopa/carbidopa/entacapone and Levodopa/carbidopa in Parkinson's Disease, sponsored by Novartis. Completed at 26 sites in Spain. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-03-15.

Sponsored by Novartis · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing levodopa in Parkinson Disease — 3 open to participants now, 3 under way, none of them phase 3. Levodopa · Parkinson Disease.

Enrollment
17th of 50
95 · median 56
Started
2006
with 2 others
Phase 4
17 of 51
3 open now
Registered
13th of 51
by date
Lead sponsor
4 of 51
Novartis

Among the 51 studies testing levodopa in Parkinson Disease, this one is the 17th largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2006, is one of 17 in phase 4, and was the 13th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

3 of the 51 studies testing levodopa in Parkinson Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About levodopa

Levodopa: first FDA approval 1970 (LARODOPA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing levodopa in Parkinson Disease, or all of them as a file.
02

Study summary

The study evaluated the efficacy of levodopa/carbidopa/entacapone vs levodopa/carbidopa in patients with Parkinson's disease and early wearing-off with levodopa

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Parkinson's disease, adults, levodopa/carbidopa/entacapone, wearing-off, activities of daily living
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients ages ≥ 30 and ≤ 80 years old.
  2. A clinical diagnosis of idiopathic Parkinson's disease.
  3. Taking a stable dose of levodopa/carbidopa (≥ 300 and ≤ 600mg) for a period of at least 1 month prior to study entry.
  4. Must be using any of the following levodopa/carbidopa standard formulation levodopa/carbidopa 100/25mg dose in any intake of the day.

    • 1 full tablet, and/or
    • 1½ tablets The patient can also be using, for a period of at least 1 month prior to study entry, 1 tablet of the controlled release formulation of levodopa/carbidopa 100/25 mg (marketed in Spain as Sinemet Plus retard) or 1 tablet the controlled release formulation of levodopa/carbidopa 200/50 mg (marketed in Spain as Sinemet retard) in each intake, at different doses.
  5. Must have early end-of-dose wearing-off defined by >= 2 or \<=7 positive responses to the QUICK questionnaire.
  6. Must have a minimum UPDRS part II (ADL) score of 9.
  7. Patients without dyskinesia or with mild dyskinesia.
  8. Female patients must be either or using one or more acceptable methods of .
  9. Must be capable of satisfying the requirements of the protocol and must be willing and able to give according to legal requirements.

Exclusion criteria

Exclusion Criteria:

  1. Previous or current use of entacapone.
  2. History, signs, or symptoms suggesting the diagnosis of secondary or atypical parkinsonism.
  3. Unstable Parkinson's disease patients.
  4. Patients who experience severe dyskinesia.
  5. The following levodopa/carbidopa doses and strengths are not permitted:

    • Patients taking ½ tablet of standard formulation levodopa/carbidopa 100/25
    • Patients taking standard formulation levodopa/carbidopa 100/10 or 250/25
    • Patients taking fewer than 3 or more than 6 daily intakes of standard formulation levodopa/carbidopa 100/25 (fewer than 300mg or more than 600mg of levodopa)
  6. Patients with hallucinations or psychiatric diseases related to levodopa or dopamine agonists intake. Patients with major depression.
  7. Female patients who are pregnant, trying to become pregnant or nursing (lactating) an infant.
  8. Concomitant treatment with MAO-inhibitors (except selegiline up to 10mg/day), rotigotine or neuroleptics, within 60 days prior to the screening visit.
  9. Patients with a previous history of Neuroleptic Malignant Syndrome (NMS) and/or non-traumatic rhabdomyolysis.
  10. Participated in another trial of an drug/device within the last 30 days prior to study entry.
  11. Patients who have a history of poor compliance or are in the Investigator's judgment unlikely to comply with medical regimens or study requirements.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    Levodopa/carbidopa/entacapone

    Drug: Levodopa/carbidopa/entacapone

  • Active comparator
    Levodopa/carbidopa

    Drug: Levodopa/carbidopa

Interventions

  • DrugLevodopa/carbidopa/entacapone

    Drug pages: Levodopa · Carbidopa · Entacapone

    Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa/entacapone was available in 2 oral dosage forms: 100/25/200 or 150/37.5/200 mg encapsulated tablets.

  • DrugLevodopa/carbidopa

    Drug pages: Levodopa · Carbidopa

    Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa was available in 2 oral dosage forms: One or one and one-half 100/25 mg encapsulated tablets.

06

What researchers measure

Primary outcomes

  1. Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living [ADL]) Score From Baseline to Month 3

    The UPDRS is a standardized assessment scale used to measure a patient's disease state. It is completed by a blinded rater. There are 6 parts to the UPDRS. Part II (items 5-17; total score 0-52, calculated as the sum of the individual items) measures the patient's activities of daily living. A lower total score indicates greater symptom control. A negative change score indicates improvement.

    Time frame: Baseline to end of study (Month 3)

Secondary outcomes

  1. Change in the UPDRS Part I (Mentation, Behavior, and Mood) Score From Baseline to Month 3

    The UPDRS is a standardized assessment scale used to measure a patient's disease state. It is completed by a blinded rater. There are 6 parts to the UPDRS. Part I (items 1-4; total score 0-16, calculated as the sum of the individual items) measures the patient's mentation, mood and behavior. A lower total score indicates greater symptom control. A negative change score indicates improvement.

    Time frame: Baseline to end of study (Month 3)

  2. Change in the UPDRS Part III (Motor Function) Score From Baseline to Month 3

    The UPDRS is a standardized assessment scale used to measure a patient's disease state. It is completed by a blinded rater. There are 6 parts to the UPDRS. Part III (items 18-31; total score 0-56, calculated as the sum of the individual items) measures the patient's motor function. A lower total score indicates greater symptom control. A negative change score indicates improvement.

    Time frame: Baseline to end of study (Month 3)

  3. Change in the UPDRS Part IV (Complications of Therapy) Score From Baseline to Month 3

    Part IV of the UPDRS measures complications the patient may be experiencing with therapy and was only collected at and after the visit at which the first dyskinesia or episode of wearing-off was recorded. Part IV is composed of 3 sections and 11 items: A (32-35, dyskinesia), B (36-39, clinical fluctuations, C (40-42, other complications) (total score 0-23, calculated as the sum of the individual items). A lower total score indicates greater symptom control. A negative change score indicates improvement.

    Time frame: Baseline to end of study (Month 3)

  4. Change in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to Month 3

    The PDQ-39 is an instrument used to assess quality of life in individuals with Parkinson's disease. The questionnaire provides scores on eight scales: Mobility, activities of daily living, emotions, stigma, social support, cognitions, communication, and bodily discomfort. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The total score can range from 39 to 195. A lower score indicates better quality of life. A positive change score indicates an improvement.

    Time frame: Baseline to end of study (Month 3)

  5. Patient and Investigator Global Evaluation of the Patient

    Both the patient and the investigator made an evaluation of the change in the patient's condition by rating the condition of the patient at the end of the study compared to patient's condition at baseline. The rating was made on a scale ranging from -3 to +3: (-3: Very much improved, -2: much improved, -1: mild improvement, 0: no change, +1: mild deterioration, +2: much deterioration, +3: very much deterioration). A negative score indicates improvement.

    Time frame: Baseline to end of study (Month 3)

  6. Change on the QUICK Questionnaire (QQ) Score From Baseline to Month 3

    The QQ is a self-administered questionnaire that includes 19 wearing-off (WO) symptoms (motor and non-motor). A positive answer to each of the 19 symptoms is given by patients if they presented with a symptom and the symptom disappeared after the next drug dose. Two positive answers are diagnostic of wearing-off (WO). A negative change score indicates improvement.

    Time frame: Baseline to end of study (Month 3)

07

Results

Posted Mar 15, 2011

Participant flow

Participant flow — Overall Study
MilestoneLevodopa/Carbidopa/EntacaponeLevodopa/Carbidopa
Started4649
Completed3539
Not completed1110
Withdrew: Adverse event30
Withdrew: Other810

Outcome measures

PrimaryChange in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living [ADL]) Score From Baseline to Month 3

The UPDRS is a standardized assessment scale used to measure a patient's disease state. It is completed by a blinded rater. There are 6 parts to the UPDRS. Part II (items 5-17; total score 0-52, calculated as the sum of the individual items) measures the patient's activities of daily living. A lower total score indicates greater symptom control. A negative change score indicates improvement.

Time frame:
Baseline to end of study (Month 3)
Reported as:
Mean · Units on a scale
Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living [ADL]) Score From Baseline to Month 3
Units on a scaleLevodopa/Carbidopa/EntacaponeLevodopa/Carbidopa
Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living [ADL]) Score From Baseline to Month 3-2.5 ± 2.8-0.5 ± 3.0
SecondaryChange in the UPDRS Part I (Mentation, Behavior, and Mood) Score From Baseline to Month 3

The UPDRS is a standardized assessment scale used to measure a patient's disease state. It is completed by a blinded rater. There are 6 parts to the UPDRS. Part I (items 1-4; total score 0-16, calculated as the sum of the individual items) measures the patient's mentation, mood and behavior. A lower total score indicates greater symptom control. A negative change score indicates improvement.

Time frame:
Baseline to end of study (Month 3)
Reported as:
Mean · Units on a scale
Change in the UPDRS Part I (Mentation, Behavior, and Mood) Score From Baseline to Month 3
Units on a scaleLevodopa/Carbidopa/EntacaponeLevodopa/Carbidopa
Change in the UPDRS Part I (Mentation, Behavior, and Mood) Score From Baseline to Month 3-0.5 ± 1.6-0.2 ± 1.0
SecondaryChange in the UPDRS Part III (Motor Function) Score From Baseline to Month 3

The UPDRS is a standardized assessment scale used to measure a patient's disease state. It is completed by a blinded rater. There are 6 parts to the UPDRS. Part III (items 18-31; total score 0-56, calculated as the sum of the individual items) measures the patient's motor function. A lower total score indicates greater symptom control. A negative change score indicates improvement.

Time frame:
Baseline to end of study (Month 3)
Reported as:
Mean · Units on a scale
Change in the UPDRS Part III (Motor Function) Score From Baseline to Month 3
Units on a scaleLevodopa/Carbidopa/EntacaponeLevodopa/Carbidopa
Change in the UPDRS Part III (Motor Function) Score From Baseline to Month 3-4.0 ± 4.6-1.42 ± 5.5
SecondaryChange in the UPDRS Part IV (Complications of Therapy) Score From Baseline to Month 3

Part IV of the UPDRS measures complications the patient may be experiencing with therapy and was only collected at and after the visit at which the first dyskinesia or episode of wearing-off was recorded. Part IV is composed of 3 sections and 11 items: A (32-35, dyskinesia), B (36-39, clinical fluctuations, C (40-42, other complications) (total score 0-23, calculated as the sum of the individual items). A lower total score indicates greater symptom control. A negative change score indicates improvement.

Time frame:
Baseline to end of study (Month 3)
Reported as:
Mean · Units on a scale
Change in the UPDRS Part IV (Complications of Therapy) Score From Baseline to Month 3
Units on a scaleLevodopa/Carbidopa/EntacaponeLevodopa/Carbidopa
Change in the UPDRS Part IV (Complications of Therapy) Score From Baseline to Month 3-0.6 ± 1.8-0.1 ± 1.3
SecondaryChange in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to Month 3

The PDQ-39 is an instrument used to assess quality of life in individuals with Parkinson's disease. The questionnaire provides scores on eight scales: Mobility, activities of daily living, emotions, stigma, social support, cognitions, communication, and bodily discomfort. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The total score can range from 39 to 195. A lower score indicates better quality of life. A positive change score indicates an improvement.

Time frame:
Baseline to end of study (Month 3)
Reported as:
Mean · Units on a scale
Change in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to Month 3
Units on a scaleLevodopa/Carbidopa/EntacaponeLevodopa/Carbidopa
Change in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to Month 36.3 ± 20.40.8 ± 15.6
SecondaryPatient and Investigator Global Evaluation of the Patient

Both the patient and the investigator made an evaluation of the change in the patient's condition by rating the condition of the patient at the end of the study compared to patient's condition at baseline. The rating was made on a scale ranging from -3 to +3: (-3: Very much improved, -2: much improved, -1: mild improvement, 0: no change, +1: mild deterioration, +2: much deterioration, +3: very much deterioration). A negative score indicates improvement.

Time frame:
Baseline to end of study (Month 3)
Reported as:
Mean · Units on a scale
Patient and Investigator Global Evaluation of the Patient
Units on a scaleLevodopa/Carbidopa/EntacaponeLevodopa/Carbidopa
Patient global evaluation-0.9 ± 1.1-0.4 ± 1.2
Investigator global evaluation-0.9 ± 1.0-0.3 ± 0.9
SecondaryChange on the QUICK Questionnaire (QQ) Score From Baseline to Month 3

The QQ is a self-administered questionnaire that includes 19 wearing-off (WO) symptoms (motor and non-motor). A positive answer to each of the 19 symptoms is given by patients if they presented with a symptom and the symptom disappeared after the next drug dose. Two positive answers are diagnostic of wearing-off (WO). A negative change score indicates improvement.

Time frame:
Baseline to end of study (Month 3)
Reported as:
Mean · Positive answers
Change on the QUICK Questionnaire (QQ) Score From Baseline to Month 3
Positive answersLevodopa/Carbidopa/EntacaponeLevodopa/Carbidopa
Change on the QUICK Questionnaire (QQ) Score From Baseline to Month 3-0.6 ± 1.8-0.6 ± 2.3

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levodopa/Carbidopa/Entacapone—1/45 (2.2%)10/45 (22.2%)
Levodopa/Carbidopa—1/49 (2%)3/49 (6.1%)
Most frequent serious events
Most frequent serious events
EventLevodopa/Carbidopa/EntacaponeLevodopa/Carbidopa
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/450/49
DelusionPsychiatric disorders0/451/49
Most frequent other events
Most frequent other events
EventLevodopa/Carbidopa/EntacaponeLevodopa/Carbidopa
DyskinesiaNervous system disorders7/451/49
AnxietyPsychiatric disorders5/450/49
RetchingGastrointestinal disorders3/452/49

Baseline characteristics

Age Continuous
Age Continuous(Years)Levodopa/Carbidopa/EntacaponeLevodopa/CarbidopaTotal
Mean66.40 ± 8.1866.45 ± 9.0466.43 ± 8.59
Sex: Female, Male
Sex: Female, Male(Participants)Levodopa/Carbidopa/EntacaponeLevodopa/CarbidopaTotal
Female252247
Male202747
Region of Enrollment
Region of Enrollment(participants)Levodopa/Carbidopa/EntacaponeLevodopa/CarbidopaTotal
Spain454994
08

Study locations

26 sites
  • Hospital Universitario Principe de Asturias
    Alcalá de Henares, Madrid, 28805, Spain
  • Fundación Hospital de Alcorcón
    Alcorcón (Madrid, 28922, Spain
  • Hospital General de Alicante
    Alicante, 03010, Spain
  • Centro Médico Teknon
    Barcelona, 08022, Spain
  • Hospital de la Santa Creu i de Sant Pau
    Barcelona, 08025, Spain
  • Hospital Vall d'Hebron
    Barcelona, 08025, Spain
  • Hospital Clínic i Provincial de Barcelona
    Barcelona, 08036, Spain
  • Corporació Sanitària Parc Taulí Sabadell
    Barcelona, 08208, Spain
  • Hospital General Yagüe
    Burgos, 09005, Spain
  • Hospital Universitario Virgen de las Nieves
    Granada, 18012, Spain
  • Hospital Universitari Bellvitge Princeps d'Espanya
    L'Hospitalet de Llobregat , Barcelona, 08907, Spain
  • Hospital Juan Canalejo
    La Coruña, 15002, Spain
  • Clínica Ruber
    Madrid, 28006, Spain
  • Hospital General Universitario Gregorio Marañon
    Madrid, 28007, Spain
  • Fundación Jiménez Díaz
    Madrid, 28040, Spain
  • Hospital Clínico San Carlos
    Madrid, 28040, Spain
  • Hospital 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Universitaria de Navarra
    Pamplona, 31008, Spain
  • Policlínica Gipuzkoa
    San Sebastian, 20009, Spain
  • Hospital General de Catalunya
    Sant Cugat del Valles, Barcelona, 08195, Spain
  • Hospital Universitario Virgen del Rocio
    Sevilla, 41013, Spain
  • Hospital Mutua de Terrassa
    Terrassa, Barcelona, 08221, Spain
  • Hospital Universitario de la Fe
    Valencia, 46009, Spain
  • Hospital Clínico Universitario de Valencia
    Valencia, 46010, Spain
  • Hospital Gral. de Valencia
    Valencia, 46014, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2006
First posted
Oct 25, 2006
Start
Oct 2006
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Results first posted
Mar 15, 2011
Last update
Mar 15, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00391898
Lead sponsor
Novartis
First posted
Oct 25, 2006
Start date
Oct 2006
Primary completion
Jun 2008
Completion
Jun 2008
Results posted
Mar 15, 2011
Last update
Mar 15, 2011

Study contacts

Eduard Tolosa-Sarró, Dr.
principal investigator · Hospital Clínic i Provincial de Barcelona
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Levodopa · Carbidopa · Entacapone

Start the discussion